Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection | Zendy

Huijun Zhou | Zendy; Gang Wu | Zendy; Jiming Li | Zendy; Nasheen Naidoo | Zendy; Yanxiang Xie | Zendy; Bo-Lan Feng | Zendy; Pei Wang | Zendy; Jiwei Luo | Zendy

Open Access

Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection

Author(s) -

Huijun Zhou,

Gang Wu,

Jiming Li,

Nasheen Naidoo,

Yanxiang Xie,

Bo-Lan Feng,

Pei Wang,

Jiwei Luo

Publication year - 2021

Publication title -

annals of palliative medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.546

H-Index - 19

eISSN - 2224-5839

pISSN - 2224-5820

DOI - 10.21037/apm-21-863

Subject(s) - medicine , genotype , regimen , gene , genetics , biology

Hepatitis C virus (HCV) infection is an important health threat in China to which direct acting antivirals (DAAs) are very effective. In 2019, another novel DAA glecaprevir/pibrentasvir (GLE/PIB) was officially approved. Knowledge of its cost-effectiveness would be informative for clinical decision-making but has not been evaluated. This study aims to evaluate the cost-effectiveness of GLE/PIB to inform policy-making on drug reimbursement and HCV eradication.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research